Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to $505774.0.

  • CorMedix's Capital Expenditures rose 507892.69% to $505774.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $549765.0, marking a year-over-year increase of 35575.62%. This contributed to the annual value of $115730.0 for FY2024, which is 6464.1% down from last year.
  • According to the latest figures from Q3 2025, CorMedix's Capital Expenditures is $505774.0, which was up 507892.69% from $23945.0 recorded in Q2 2025.
  • CorMedix's Capital Expenditures' 5-year high stood at $777870.0 during Q3 2021, with a 5-year trough of $4324.0 in Q1 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $19355.5 (2023), whereas its average is $144692.6.
  • As far as peak fluctuations go, CorMedix's Capital Expenditures plummeted by 9017.6% in 2022, and later soared by 507892.69% in 2025.
  • CorMedix's Capital Expenditures (Quarter) stood at $628761.0 in 2021, then tumbled by 79.52% to $128755.0 in 2022, then plummeted by 88.53% to $14766.0 in 2023, then plummeted by 33.16% to $9869.0 in 2024, then skyrocketed by 5024.88% to $505774.0 in 2025.
  • Its Capital Expenditures was $505774.0 in Q3 2025, compared to $23945.0 in Q2 2025 and $10177.0 in Q1 2025.